<DOC>
	<DOC>NCT01978912</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and exploratory efficacy of KTP-001 in subjects with lumbar disc herniation.</brief_summary>
	<brief_title>A Study to Evaluate Safety and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation</brief_title>
	<detailed_description />
	<mesh_term>Intervertebral Disc Displacement</mesh_term>
	<mesh_term>Hernia</mesh_term>
	<criteria>Subject has had a single contained or noncontained (extruded) lumbar disc herniation (L3L4, L4L5 or L5S1) diagnosed by clinical symptoms and/or physical findings and confirmed by MRI. Subject has leg pain with a documented positive straight leg raise (SLR) test or femoral stretch test (FST). Subject has experiences herniated disc symptoms for at least 6 weeks prior to the study without relief with pain medications and other therapies. Subject has a BMI of 18 to 35 kg/m2 Subject has a sequestered lumbar disc herniation or intrathecal herniation confirmed by MRI Subject has two or more symptomatic lumbar disc herniations Previous intradiscal therapeutic intervention or has had any lumbar surgery Presence of lumbar spine disease and/or deformity other than a lumbar disc herniation Active smoker or is unable to abstain from tobacco use for 2 weeks prior to study injection Subject has a history or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>